To include your compound in the COVID-19 Resource Center, submit it here.

Teva slashing workforce amid restructuring

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv: TEVA) gained $1.60 (10%) to $17.30 in New York on Thursday after disclosing details of its restructuring plan, which includes reducing global headcount by 14,000 jobs, or 26%, to 39,000 over the next two years. Teva expects the cuts,

Read the full 468 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE